This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Sage Therapeutics Management
Management criteria checks 1/4
Sage Therapeutics' CEO is Barry Greene, appointed in Dec 2020, has a tenure of 4.67 years. total yearly compensation is $7.11M, comprised of 11.7% salary and 88.3% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $869.48K. The average tenure of the management team and the board of directors is 0.8 years and 10 years respectively.
Key information
Barry Greene
Chief executive officer
US$7.1m
Total compensation
| CEO salary percentage | 11.68% |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | less than a year |
| Board average tenure | 10yrs |
Recent management updates
Recent updates
New Narrative • Mar 29
Expanding ZURZUVAE Demand Will Improve Postpartum And Neuropsych Care
Establishing ZURZUVAE as the PPD care standard should drive top-line growth through increased demand and brand visibility.Seeking Alpha • Jan 22
Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid
Summary Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid for SAGE at $7.22 per share, which seems exceedingly cheap, considering SAGE has a lot of cash, and Zurzuvae is just ramping up its sales. SAGE is now contesting the takeover, which could lead to higher follow-up bids. This, I believe, adds upside optionality to the stock. Zurzuvae is also a relatively unique IP for PPD, as it has a simple 14-day regime that provides quick relief for depressive symptoms. This is why I think SAGE stock is a good buy at these levels. It seems undervalued as a standalone company or a takeover target with BIIB. Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Summary The company remains a "hold" due to Biogen's unsolicited offer to acquire shares at a 30% premium, despite pipeline setbacks. The failure of the phase 2 DIMENSION study for dalzanemdor in treating cognitive impairment in Huntington's Disease highlights Sage's shrinking pipeline. Sage's financials indicate a need for additional funding in 2025, risking dilution and further financial instability. The future of SAGE-324 and SAGE-319 remains uncertain in treating patients with neurodevelopmental disorders, adding risk to the company's long-term prospects. Read the full article on Seeking AlphaSeeking Alpha • Nov 19
CNS Drug Development: Same As It Ever Was
Summary Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as well. They have a clinical trial readout in Huntington's disease later this fall, and man, that's a tough place to make your stand. Read the full article on Seeking AlphaSeeking Alpha • Oct 07
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Summary Sage Therapeutics is a "sell" due to the failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's Disease. Dalzanemdor's upcoming phase 2 studies for Huntington's and Alzheimer's diseases are unlikely to succeed, given prior trial results and similar primary endpoints. Financially, Sage has enough cash to operate until 2026, but without successful trials, raising additional funds will be challenging. Despite FDA approval of Zurzuvae for postpartum depression, it won't drive long-term growth; dalzanemdor's success is crucial for shareholder value creation. Read the full article on Seeking AlphaAnalysis Article • Aug 30
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders that were waiting for something to happen have been dealt a blow...Seeking Alpha • Jul 25
Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Summary Sage Therapeutics, Inc.'s SAGE-324 failed its Phase 2b trial for essential tremor and development is discontinued. Dalzanemdor's past data in Parkinson's casts doubt on its prospects in other cognitive disorders. Zurzuvae's Q1 revenue exceeded expectations, but the market potential remains constrained by its narrow indication. Analysts are expecting $8.90 million in revenue for Q2. While Sage may exceed this, it isn't likely to move the stock much. Given clinical setbacks and limited revenue growth, I recommend downgrading Sage Therapeutics to “sell.”. Read the full article on Seeking AlphaAnalysis Article • Jul 13
Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 7.8x Sage Therapeutics, Inc. ( NASDAQ:SAGE ) is a stock...Seeking Alpha • May 30
Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
Summary Sage Therapeutics, Inc. results from phase 2b KINETIC 2 Study, using SAGE-324 for the treatment of patients with essential tremor, expected mid-2024. Top-line data from the phase 3 SURVEYOR study, using SAGE-718 for cognitive impairment in HD patients, expected in mid-2024. Top-line data from the phase 2 DIMENSION study, using SAGE-718 for cognitive impairment in HD patients, expected late-2024. Top-line data from the phase 2 LIGHTWAVE Study, using SAGE-718 for mild cognitive impairment or mild dementia due to Alzheimer's Disease, expected late-2024. Read the full article on Seeking AlphaAnalysis Article • May 21
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysis Article • Feb 22
Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
The analysts covering Sage Therapeutics, Inc. ( NASDAQ:SAGE ) delivered a dose of negativity to shareholders today, by...Analysis Article • Feb 15
Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Key Insights Sage Therapeutics' estimated fair value is US$29.43 based on 2 Stage Free Cash Flow to Equity Sage...Seeking Alpha • Jan 22
Sizing Up Sage Therapeutics
Summary Today, we take a deeper look at Sage Therapeutics, Inc., a biopharmaceutical company focused on developing brain health medicines. The stock has fallen sharply since June on a more limited FDA approval for the company's primary drug candidate. The drug has just been launched and management has taken actions to substantially lower annual operating costs. What's ahead for Sage Therapeutics in 2024? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Today is shaping up negative for Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders, with the analysts delivering a...Analysis Article • Feb 22
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Nov 12
An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Today we will run through one way of estimating the intrinsic value of Sage Therapeutics, Inc. ( NASDAQ:SAGE ) by...Analysis Article • Oct 14
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Aug 02
Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Sage Therapeutics press release (NASDAQ:SAGE): Q2 GAAP EPS of -$2.13 beats by $0.02. Revenue of $1.5M (-8.5% Y/Y) misses by $0.27M. Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2022 were $1.5 billion compared to $1.6 billion at March 31, 2022 Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022 Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD Enrolling multiple Phase 2 studies across neuropsychiatry and neurology franchises, additional trials expected to initiate throughout 2022 Cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, expected to support operations into 2025Analysis Article • Jun 15
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 24
Sage Therapeutics: Well-Funded But Uninspiring Data
Sage is well funded by Biogen. However, lead candidate SAGE-217 has not come up with strong MDD data. I continue to sit on the fence.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$301m |
| Mar 31 2025 | n/a | n/a | -US$354m |
| Dec 31 2024 | US$7m | US$831k | -US$401m |
| Sep 30 2024 | n/a | n/a | -US$338m |
| Jun 30 2024 | n/a | n/a | -US$446m |
| Mar 31 2024 | n/a | n/a | -US$503m |
| Dec 31 2023 | US$6m | US$799k | -US$541m |
| Sep 30 2023 | n/a | n/a | -US$656m |
| Jun 30 2023 | n/a | n/a | -US$592m |
| Mar 31 2023 | n/a | n/a | -US$558m |
| Dec 31 2022 | US$6m | US$761k | -US$533m |
| Sep 30 2022 | n/a | n/a | -US$510m |
| Jun 30 2022 | n/a | n/a | -US$503m |
| Mar 31 2022 | n/a | n/a | -US$484m |
| Dec 31 2021 | US$59m | US$735k | -US$458m |
| Sep 30 2021 | n/a | n/a | US$642m |
| Jun 30 2021 | n/a | n/a | US$666m |
| Mar 31 2021 | n/a | n/a | US$637m |
| Dec 31 2020 | US$836k | US$53k | US$606m |
Compensation vs Market: Barry's total compensation ($USD7.11M) is above average for companies of similar size in the US market ($USD2.53M).
Compensation vs Earnings: Barry's compensation has increased whilst the company is unprofitable.
CEO
Barry Greene (62 yo)
4.7yrs
Tenure
US$7,112,589
Compensation
Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and serves as Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.7yrs | US$7.11m | 0.16% $ 869.5k | |
| COO & Treasurer | less than a year | US$2.60m | 0.019% $ 104.6k | |
| Senior VP | less than a year | US$1.17m | no data | |
| Chief Scientific Officer & Interim Head of R&D | 2yrs | no data | 0.049% $ 264.4k | |
| Director of Investor Relations | no data | no data | no data | |
| Senior VP and Chief People & Experience Officer | less than a year | no data | no data | |
| Senior Vice President of Drug Safety & Pharmacovigilance | no data | no data | no data | |
| Medical Director of Early Clinical Development | no data | no data | no data | |
| Investor Relations Officer | no data | no data | no data |
0.8yrs
Average Tenure
Experienced Management: SAGE's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$7.11m | 0.16% $ 869.5k | |
| Independent Director | 10.9yrs | US$167.22k | 0% $ 0 | |
| Independent Director | 11.3yrs | US$169.31k | 0.0045% $ 24.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chair of the Board | 9.1yrs | US$190.49k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
10.0yrs
Average Tenure
64yo
Average Age
Experienced Board: SAGE's board of directors are seasoned and experienced ( 10 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/01 20:25 |
| End of Day Share Price | 2025/07/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sage Therapeutics, Inc. is covered by 9 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| null null | BMO Capital Markets Equity Research |
| Gary Nachman | BMO Capital Markets Equity Research |